25 XP   0   0   10

Ilsung Pharm
Buy, Hold or Sell?

Let's analyse Ilsung Pharm together

PenkeI guess you are interested in Ilsung Pharm. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Ilsung Pharm. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Ilsung Pharm

I send you an email if I find something interesting about Ilsung Pharm.

Quick analysis of Ilsung Pharm (30 sec.)










What can you expect buying and holding a share of Ilsung Pharm? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
72.4%

What is your share worth?

Current worth
₩56,157.87
Expected worth in 1 year
₩46,941.80
How sure are you?
79.3%

+ What do you gain per year?

Total Gains per Share
₩-9,216.07
Return On Investment
-46.8%

For what price can you sell your share?

Current Price per Share
₩19,700.00
Expected price per share
₩18,070 - ₩24,600
How sure are you?
50%

1. Valuation of Ilsung Pharm (5 min.)




Live pricePrice per Share (EOD)

₩19,700.00

Intrinsic Value Per Share

₩-113,596.26 - ₩-133,494.71

Total Value Per Share

₩-57,438.39 - ₩-77,336.84

2. Growth of Ilsung Pharm (5 min.)




Is Ilsung Pharm growing?

Current yearPrevious yearGrowGrow %
How rich?$267.9m$292.7m-$4.8m-1.7%

How much money is Ilsung Pharm making?

Current yearPrevious yearGrowGrow %
Making money-$3.6m$18.4m-$22m-602.6%
Net Profit Margin-18.8%199.7%--

How much money comes from the company's main activities?

3. Financial Health of Ilsung Pharm (5 min.)




What can you expect buying and holding a share of Ilsung Pharm? (5 min.)

Welcome investor! Ilsung Pharm's management wants to use your money to grow the business. In return you get a share of Ilsung Pharm.

What can you expect buying and holding a share of Ilsung Pharm?

First you should know what it really means to hold a share of Ilsung Pharm. And how you can make/lose money.

Speculation

The Price per Share of Ilsung Pharm is ₩19,700. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Ilsung Pharm.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Ilsung Pharm, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩56,157.87. Based on the TTM, the Book Value Change Per Share is ₩-2,304.02 per quarter. Based on the YOY, the Book Value Change Per Share is ₩3,655.46 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Ilsung Pharm.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-4.080.0%-0.560.0%2.700.0%0.470.0%0.350.0%
Usd Book Value Change Per Share-3.800.0%-1.610.0%2.560.0%0.300.0%1.360.0%
Usd Dividend Per Share0.000.0%0.000.0%0.060.0%0.070.0%0.080.0%
Usd Total Gains Per Share-3.800.0%-1.610.0%2.620.0%0.370.0%1.440.0%
Usd Price Per Share16.56-17.35-12.19-12.86-14.06-
Price to Earnings Ratio-1.01--6.65-20.28-68.44-24.84-
Price-to-Total Gains Ratio-4.36-10.00-23.93-31.15-55.51-
Price to Book Ratio0.42-0.42-0.29-0.34-0.39-
Price-to-Total Gains Ratio-4.36-10.00-23.93-31.15-55.51-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share13.79
Number of shares72
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.07
Usd Book Value Change Per Share-1.610.30
Usd Total Gains Per Share-1.610.37
Gains per Quarter (72 shares)-116.1226.60
Gains per Year (72 shares)-464.49106.39
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-464-474208696
20-929-93840173202
30-1393-140260259308
40-1858-186680346414
50-2322-2330100432520
60-2787-2794120518626
70-3251-3258140605732
80-3716-3722160691838
90-4180-4186180778944
100-4645-46502008641050

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%9.03.00.075.0%16.04.00.080.0%23.06.00.079.3%23.06.00.079.3%
Book Value Change Per Share2.02.00.050.0%8.04.00.066.7%13.07.00.065.0%21.08.00.072.4%21.08.00.072.4%
Dividend per Share0.00.04.00.0%6.00.06.050.0%12.00.08.060.0%21.00.08.072.4%21.00.08.072.4%
Total Gains per Share2.02.00.050.0%8.04.00.066.7%14.06.00.070.0%23.06.00.079.3%23.06.00.079.3%

Fundamentals of Ilsung Pharm

About Ilsung Pharm

Ilsung Pharmaceuticals Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, adrenal cortical steroids, anesthetics, antipyretics, and cardiovascular system products. Ilsung Pharmaceuticals Co., Ltd. was founded in 1954 and is headquartered in Seoul, South Korea.

Fundamental data was last updated by Penke on 2024-04-14 20:32:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Ilsung Pharm.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Ilsung Pharm earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Ilsung Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -180.3% means that ₩-1.80 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ilsung Pharm:

  • The MRQ is -180.3%. The company is making a huge loss. -2
  • The TTM is -18.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-180.3%TTM-18.8%-161.5%
TTM-18.8%YOY199.7%-218.5%
TTM-18.8%5Y39.0%-57.7%
5Y39.0%10Y28.2%+10.8%
1.1.2. Return on Assets

Shows how efficient Ilsung Pharm is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Ilsung Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • -9.5% Return on Assets means that Ilsung Pharm generated ₩-0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ilsung Pharm:

  • The MRQ is -9.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.5%TTM-1.4%-8.1%
TTM-1.4%YOY5.4%-6.8%
TTM-1.4%5Y0.9%-2.3%
5Y0.9%10Y0.7%+0.2%
1.1.3. Return on Equity

Shows how efficient Ilsung Pharm is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Ilsung Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • -10.4% Return on Equity means Ilsung Pharm generated ₩-0.10 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ilsung Pharm:

  • The MRQ is -10.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -1.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.4%TTM-1.5%-8.9%
TTM-1.5%YOY6.0%-7.5%
TTM-1.5%5Y1.0%-2.5%
5Y1.0%10Y0.8%+0.2%

1.2. Operating Efficiency of Ilsung Pharm.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Ilsung Pharm is operating .

  • Measures how much profit Ilsung Pharm makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Ilsung Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ilsung Pharm:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY1.4%-1.4%
TTM-5Y1.8%-1.8%
5Y1.8%10Y2.3%-0.5%
1.2.2. Operating Ratio

Measures how efficient Ilsung Pharm is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 2.41 means that the operating costs are ₩2.41 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Ilsung Pharm:

  • The MRQ is 2.412. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.838. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.412TTM1.838+0.574
TTM1.838YOY1.330+0.508
TTM1.8385Y1.600+0.238
5Y1.60010Y1.596+0.003

1.3. Liquidity of Ilsung Pharm.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Ilsung Pharm is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 8.42 means the company has ₩8.42 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Ilsung Pharm:

  • The MRQ is 8.424. The company is very able to pay all its short-term debts. +2
  • The TTM is 10.316. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ8.424TTM10.316-1.892
TTM10.316YOY9.748+0.568
TTM10.3165Y12.578-2.262
5Y12.57810Y14.923-2.345
1.3.2. Quick Ratio

Measures if Ilsung Pharm is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Ilsung Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 2.83 means the company can pay off ₩2.83 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ilsung Pharm:

  • The MRQ is 2.827. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.897. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.827TTM1.897+0.930
TTM1.897YOY2.888-0.990
TTM1.8975Y6.421-4.524
5Y6.42110Y9.546-3.125

1.4. Solvency of Ilsung Pharm.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Ilsung Pharm assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Ilsung Pharm to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.09 means that Ilsung Pharm assets are financed with 8.7% credit (debt) and the remaining percentage (100% - 8.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Ilsung Pharm:

  • The MRQ is 0.087. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.096. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.087TTM0.096-0.009
TTM0.096YOY0.093+0.004
TTM0.0965Y0.079+0.017
5Y0.07910Y0.075+0.004
1.4.2. Debt to Equity Ratio

Measures if Ilsung Pharm is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Ilsung Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 9.5% means that company has ₩0.10 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ilsung Pharm:

  • The MRQ is 0.095. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.108. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.095TTM0.108-0.013
TTM0.108YOY0.102+0.005
TTM0.1085Y0.086+0.022
5Y0.08610Y0.082+0.005

2. Market Valuation of Ilsung Pharm

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Ilsung Pharm generates.

  • Above 15 is considered overpriced but always compare Ilsung Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -1.01 means the investor is paying ₩-1.01 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ilsung Pharm:

  • The EOD is -0.845. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.015. Based on the earnings, the company is expensive. -2
  • The TTM is -6.649. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.845MRQ-1.015+0.170
MRQ-1.015TTM-6.649+5.634
TTM-6.649YOY20.277-26.926
TTM-6.6495Y68.438-75.087
5Y68.43810Y24.838+43.600
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Ilsung Pharm:

  • The EOD is -2.304. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.765. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.725. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.304MRQ-2.765+0.462
MRQ-2.765TTM-3.725+0.960
TTM-3.725YOY-88.396+84.670
TTM-3.7255Y-20.674+16.949
5Y-20.67410Y-14.258-6.416
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Ilsung Pharm is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 0.42 means the investor is paying ₩0.42 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Ilsung Pharm:

  • The EOD is 0.351. Based on the equity, the company is cheap. +2
  • The MRQ is 0.421. Based on the equity, the company is cheap. +2
  • The TTM is 0.417. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.351MRQ0.421-0.070
MRQ0.421TTM0.417+0.004
TTM0.417YOY0.286+0.132
TTM0.4175Y0.340+0.077
5Y0.34010Y0.391-0.051
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Ilsung Pharm compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---5427.607-2304.018-58%3655.459-248%428.560-1366%1936.478-380%
Book Value Per Share--56157.87059495.311-6%61363.883-8%54058.357+4%51990.636+8%
Current Ratio--8.42410.316-18%9.748-14%12.578-33%14.923-44%
Debt To Asset Ratio--0.0870.096-10%0.093-6%0.079+10%0.075+16%
Debt To Equity Ratio--0.0950.108-12%0.102-7%0.086+10%0.082+17%
Dividend Per Share----0%84.388-100%99.175-100%114.287-100%
Eps---5825.423-798.738-86%3860.266-251%675.185-963%499.020-1267%
Free Cash Flow Per Share---2137.957-1787.407-16%-3721.636+74%-1470.557-31%-1470.557-31%
Free Cash Flow To Equity Per Share---2137.957-1787.407-16%-3932.043+84%-1549.909-28%-1549.909-28%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---133494.709--------
Intrinsic Value_10Y_min---113596.264--------
Intrinsic Value_1Y_max---8519.541--------
Intrinsic Value_1Y_min---8365.401--------
Intrinsic Value_3Y_max---29299.807--------
Intrinsic Value_3Y_min---27897.279--------
Intrinsic Value_5Y_max---54543.472--------
Intrinsic Value_5Y_min---50307.208--------
Market Cap134268699000.000-20%161190666450.000171624119662.500-6%118728971400.000+36%125804746672.500+28%137226055029.310+17%
Net Profit Margin---1.803-0.188-90%1.997-190%0.390-563%0.282-739%
Operating Margin----0%0.014-100%0.018-100%0.023-100%
Operating Ratio--2.4121.838+31%1.330+81%1.600+51%1.596+51%
Pb Ratio0.351-20%0.4210.417+1%0.286+47%0.340+24%0.391+8%
Pe Ratio-0.845+17%-1.015-6.649+555%20.277-105%68.438-101%24.838-104%
Price Per Share19700.000-20%23650.00024782.500-5%17420.000+36%18378.500+29%20078.966+18%
Price To Free Cash Flow Ratio-2.304+17%-2.765-3.725+35%-88.396+3096%-20.674+648%-14.258+416%
Price To Total Gains Ratio-3.630+17%-4.3579.998-144%23.925-118%31.151-114%55.509-108%
Quick Ratio--2.8271.897+49%2.888-2%6.421-56%9.546-70%
Return On Assets---0.095-0.014-85%0.054-275%0.009-1134%0.007-1457%
Return On Equity---0.104-0.015-86%0.060-274%0.010-1115%0.008-1438%
Total Gains Per Share---5427.607-2304.018-58%3739.848-245%527.735-1128%2050.765-365%
Usd Book Value--267927576.014287877495.099-7%292765184.427-8%258716184.841+4%248601187.381+8%
Usd Book Value Change Per Share---3.799-1.613-58%2.559-248%0.300-1366%1.356-380%
Usd Book Value Per Share--39.31141.647-6%42.955-8%37.841+4%36.393+8%
Usd Dividend Per Share----0%0.059-100%0.069-100%0.080-100%
Usd Eps---4.078-0.559-86%2.702-251%0.473-963%0.349-1267%
Usd Free Cash Flow---10200132.775-8610298.288-16%-17755810.280+74%-5629314.330-45%-3882285.745-62%
Usd Free Cash Flow Per Share---1.497-1.251-16%-2.605+74%-1.029-31%-1.029-31%
Usd Free Cash Flow To Equity Per Share---1.497-1.251-16%-2.752+84%-1.085-28%-1.085-28%
Usd Market Cap93988089.300-20%112833466.515120136883.764-6%83110279.980+36%88063322.671+28%96058238.521+17%
Usd Price Per Share13.790-20%16.55517.348-5%12.194+36%12.865+29%14.055+18%
Usd Profit---27792924.446-3664656.317-87%18417208.485-251%3250505.806-955%2400959.419-1258%
Usd Revenue--15415020.60713659315.621+13%10718373.073+44%9464114.581+63%10049546.048+53%
Usd Total Gains Per Share---3.799-1.613-58%2.618-245%0.369-1128%1.436-365%
 EOD+3 -5MRQTTM+5 -27YOY+12 -235Y+8 -2710Y+8 -27

3.2. Fundamental Score

Let's check the fundamental score of Ilsung Pharm based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.845
Price to Book Ratio (EOD)Between0-10.351
Net Profit Margin (MRQ)Greater than0-1.803
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.827
Current Ratio (MRQ)Greater than18.424
Debt to Asset Ratio (MRQ)Less than10.087
Debt to Equity Ratio (MRQ)Less than10.095
Return on Equity (MRQ)Greater than0.15-0.104
Return on Assets (MRQ)Greater than0.05-0.095
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Ilsung Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.152
Ma 20Greater thanMa 5020,371.000
Ma 50Greater thanMa 10021,850.400
Ma 100Greater thanMa 20022,388.700
OpenGreater thanClose20,000.000
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets419,189,929
Total Liabilities36,436,249
Total Stockholder Equity382,753,680
 As reported
Total Liabilities 36,436,249
Total Stockholder Equity+ 382,753,680
Total Assets = 419,189,929

Assets

Total Assets419,189,929
Total Current Assets293,943,117
Long-term Assets125,246,813
Total Current Assets
Cash And Cash Equivalents 160,085,707
Short-term Investments 75,334,487
Net Receivables 23,301,415
Inventory 31,240,779
Other Current Assets 0
Total Current Assets  (as reported)293,943,117
Total Current Assets  (calculated)289,962,388
+/- 3,980,729
Long-term Assets
Property Plant Equipment 69,750,301
Intangible Assets 2,378,136
Long-term Assets  (as reported)125,246,813
Long-term Assets  (calculated)72,128,438
+/- 53,118,375

Liabilities & Shareholders' Equity

Total Current Liabilities34,892,112
Long-term Liabilities1,544,138
Total Stockholder Equity382,753,680
Total Current Liabilities
Accounts payable 5,763,557
Other Current Liabilities 1,753,803
Total Current Liabilities  (as reported)34,892,112
Total Current Liabilities  (calculated)7,517,360
+/- 27,374,752
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt238,126
Long-term Liabilities  (as reported)1,544,138
Long-term Liabilities  (calculated)238,126
+/- 1,306,012
Total Stockholder Equity
Retained Earnings 459,164,063
Total Stockholder Equity (as reported)382,753,680
Total Stockholder Equity (calculated)459,164,063
+/- 76,410,383
Other
Capital Stock13,300,000
Common Stock Shares Outstanding 6,816
Net Invested Capital 382,753,680
Net Working Capital 259,051,005
Property Plant and Equipment Gross 122,342,295



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
338,501,960
345,230,855
344,481,592
347,261,914
347,461,710
348,790,524
347,472,956
347,343,299
347,264,433
349,731,775
351,115,723
352,109,983
369,516,179
369,865,208
368,924,162
366,910,485
371,224,516
367,487,270
367,944,107
367,590,052
371,382,501
370,073,945
487,206,598
494,647,621
494,420,098
498,851,966
450,913,420
454,308,977
419,189,929
419,189,929454,308,977450,913,420498,851,966494,420,098494,647,621487,206,598370,073,945371,382,501367,590,052367,944,107367,487,270371,224,516366,910,485368,924,162369,865,208369,516,179352,109,983351,115,723349,731,775347,264,433347,343,299347,472,956348,790,524347,461,710347,261,914344,481,592345,230,855338,501,960
   > Total Current Assets 
270,170,748
277,123,835
280,721,587
284,270,601
278,810,035
277,226,988
276,303,377
275,965,099
279,421,732
275,736,882
277,661,278
265,857,756
272,440,820
275,807,652
277,711,394
255,700,584
263,248,192
272,764,703
284,310,615
280,045,390
279,964,900
275,289,853
397,912,897
403,214,504
343,905,674
350,052,433
299,481,427
303,852,725
293,943,117
293,943,117303,852,725299,481,427350,052,433343,905,674403,214,504397,912,897275,289,853279,964,900280,045,390284,310,615272,764,703263,248,192255,700,584277,711,394275,807,652272,440,820265,857,756277,661,278275,736,882279,421,732275,965,099276,303,377277,226,988278,810,035284,270,601280,721,587277,123,835270,170,748
       Cash And Cash Equivalents 
19,872,850
25,496,765
33,824,481
34,758,633
29,521,990
31,384,722
31,098,131
26,453,805
1,391,931
1,443,515
1,169,566
730,833
37,278,164
40,040,905
40,708,778
24,473,429
36,219,730
48,774,933
53,573,931
50,625,164
50,844,178
45,306,583
355,327,054
347,984,428
272,920,290
280,535,825
223,385,557
221,519,660
160,085,707
160,085,707221,519,660223,385,557280,535,825272,920,290347,984,428355,327,05445,306,58350,844,17850,625,16453,573,93148,774,93336,219,73024,473,42940,708,77840,040,90537,278,164730,8331,169,5661,443,5151,391,93126,453,80531,098,13131,384,72229,521,99034,758,63333,824,48125,496,76519,872,850
       Short-term Investments 
13,887,441
13,740,532
12,033,711
10,727,575
11,249,327
8,257,800
3,672,155
3,642,692
42,483,347
48,808,327
42,227,256
41,724,526
14,688,513
14,977,073
19,327,935
14,369,363
9,025,356
3,681,348
12,990,227
13,216,324
13,242,313
10,643,058
11,124,667
20,957,653
27,010,894
27,286,472
25,351,232
25,451,967
75,334,487
75,334,48725,451,96725,351,23227,286,47227,010,89420,957,65311,124,66710,643,05813,242,31313,216,32412,990,2273,681,3489,025,35614,369,36319,327,93514,977,07314,688,51341,724,52642,227,25648,808,32742,483,3473,642,6923,672,1558,257,80011,249,32710,727,57512,033,71113,740,53213,887,441
       Net Receivables 
215,968,527
215,933,690
214,114,792
215,743,641
214,366,054
217,610,196
213,564,403
208,860,269
207,862,564
15,954,686
16,030,031
14,573,530
204,427,930
205,477,722
202,137,612
201,947,510
202,574,303
204,222,526
202,434,555
201,592,860
201,872,086
204,207,223
14,213,150
14,862,394
16,600,440
17,084,527
19,041,841
19,846,163
23,301,415
23,301,41519,846,16319,041,84117,084,52716,600,44014,862,39414,213,150204,207,223201,872,086201,592,860202,434,555204,222,526202,574,303201,947,510202,137,612205,477,722204,427,93014,573,53016,030,03115,954,686207,862,564208,860,269213,564,403217,610,196214,366,054215,743,641214,114,792215,933,690215,968,527
       Inventory 
20,109,534
21,197,558
20,266,942
22,793,063
23,022,722
19,359,943
17,813,732
18,843,186
15,386,048
15,305,139
15,417,018
16,062,264
14,147,009
13,222,211
14,657,352
14,746,163
13,132,378
13,547,295
13,756,209
12,714,963
12,478,266
13,247,103
15,201,946
18,292,645
20,641,295
22,815,287
28,977,300
35,037,078
31,240,779
31,240,77935,037,07828,977,30022,815,28720,641,29518,292,64515,201,94613,247,10312,478,26612,714,96313,756,20913,547,29513,132,37814,746,16314,657,35213,222,21114,147,00916,062,26415,417,01815,305,13915,386,04818,843,18617,813,73219,359,94323,022,72222,793,06320,266,94221,197,55820,109,534
       Other Current Assets 
319,828
729,738
465,270
218,204
631,059
585,054
842,474
5,014,883
2,237,713
456,328
329,864
79,023
1,878,849
2,057,230
820,478
119,426
2,266,852
2,492,384
1,529,544
1,847,968
1,496,722
1,842,162
1,694,474
1,064,812
3,102,835
0
0
-1
0
0-1003,102,8351,064,8121,694,4741,842,1621,496,7221,847,9681,529,5442,492,3842,266,852119,426820,4782,057,2301,878,84979,023329,864456,3282,237,7135,014,883842,474585,054631,059218,204465,270729,738319,828
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
73,994,893
73,454,445
86,252,226
97,075,358
94,057,555
91,212,768
111,209,901
107,976,323
94,722,567
83,633,492
87,544,662
91,417,601
94,784,091
89,293,701
91,433,117
150,514,424
148,799,533
151,431,993
150,456,252
125,246,813
125,246,813150,456,252151,431,993148,799,533150,514,42491,433,11789,293,70194,784,09191,417,60187,544,66283,633,49294,722,567107,976,323111,209,90191,212,76894,057,55597,075,35886,252,22673,454,44573,994,893000000000
       Property Plant Equipment 
28,513,954
28,400,366
27,888,113
27,461,418
27,087,360
26,737,977
26,508,931
26,085,871
25,678,401
25,386,729
25,050,762
24,517,444
24,110,923
23,494,252
23,665,729
23,407,180
26,038,458
25,639,818
27,211,593
30,176,027
33,111,585
32,565,495
36,287,972
36,121,597
92,649,325
92,490,968
82,909,339
84,320,416
69,750,301
69,750,30184,320,41682,909,33992,490,96892,649,32536,121,59736,287,97232,565,49533,111,58530,176,02727,211,59325,639,81826,038,45823,407,18023,665,72923,494,25224,110,92324,517,44425,050,76225,386,72925,678,40126,085,87126,508,93126,737,97727,087,36027,461,41827,888,11328,400,36628,513,954
       Long Term Investments 
39,138,128
39,029,025
35,103,806
34,768,309
40,803,729
43,688,853
43,900,062
44,416,172
38,354,226
44,804,173
44,605,775
57,942,956
69,178,842
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000069,178,84257,942,95644,605,77544,804,17338,354,22644,416,17243,900,06243,688,85340,803,72934,768,30935,103,80639,029,02539,138,128
       Intangible Assets 
223,588
222,088
220,588
219,088
218,088
218,088
218,088
333,658
327,575
321,493
315,410
309,327
303,245
297,162
291,080
284,997
278,914
272,832
329,832
506,766
1,918,984
1,909,718
2,041,202
2,329,936
2,290,503
2,299,404
2,395,405
2,392,196
2,378,136
2,378,1362,392,1962,395,4052,299,4042,290,5032,329,9362,041,2021,909,7181,918,984506,766329,832272,832278,914284,997291,080297,162303,245309,327315,410321,493327,575333,658218,088218,088218,088219,088220,588222,088223,588
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
-1
182,190
0
-1
0
0
0
0
0
0
0
0
0
0
0
0
-1
1
0
0
001-1000000000000-10182,190-1000000000
> Total Liabilities 
18,401,134
23,212,275
21,601,646
24,209,114
24,635,480
25,324,373
23,171,853
23,022,931
22,929,384
26,159,556
23,880,814
25,560,479
24,026,726
26,139,318
24,961,133
22,616,630
23,748,423
26,307,937
26,011,397
24,983,811
25,472,910
28,011,441
46,168,776
50,371,245
48,852,889
71,704,910
35,546,370
34,562,506
36,436,249
36,436,24934,562,50635,546,37071,704,91048,852,88950,371,24546,168,77628,011,44125,472,91024,983,81126,011,39726,307,93723,748,42322,616,63024,961,13326,139,31824,026,72625,560,47923,880,81426,159,55622,929,38423,022,93123,171,85325,324,37324,635,48024,209,11421,601,64623,212,27518,401,134
   > Total Current Liabilities 
9,117,388
13,843,221
11,916,126
14,394,167
15,511,392
16,403,999
15,576,639
15,279,366
15,904,261
19,008,658
16,644,523
18,213,460
18,316,063
21,229,832
20,383,826
16,832,002
16,824,291
21,855,517
21,309,253
20,191,868
20,726,994
23,704,485
39,640,296
43,539,375
42,557,942
63,602,618
22,621,350
21,553,042
34,892,112
34,892,11221,553,04222,621,35063,602,61842,557,94243,539,37539,640,29623,704,48520,726,99420,191,86821,309,25321,855,51716,824,29116,832,00220,383,82621,229,83218,316,06318,213,46016,644,52319,008,65815,904,26115,279,36615,576,63916,403,99915,511,39214,394,16711,916,12613,843,2219,117,388
       Accounts payable 
1,273,344
4,587,864
2,407,502
4,606,949
5,286,466
2,436,635
3,033,555
2,740,241
2,322,204
3,016,881
2,380,628
2,443,689
2,328,871
2,681,385
3,865,142
1,718,669
2,100,115
3,753,430
2,578,926
1,237,572
758,275
3,016,206
2,122,030
5,362,732
5,050,468
4,631,223
7,172,509
7,773,418
5,763,557
5,763,5577,773,4187,172,5094,631,2235,050,4685,362,7322,122,0303,016,206758,2751,237,5722,578,9263,753,4302,100,1151,718,6693,865,1422,681,3852,328,8712,443,6892,380,6283,016,8812,322,2042,740,2413,033,5552,436,6355,286,4664,606,9492,407,5024,587,8641,273,344
       Other Current Liabilities 
2,405,039
3,749,635
2,443,038
2,195,942
2,684,513
7,333,478
7,378,103
7,032,281
7,584,075
2,117,656
2,125,758
1,919,171
11,017,510
14,396,767
12,171,072
10,788,140
10,319,277
13,762,059
14,233,236
14,416,367
15,117,612
15,774,878
32,281,558
33,049,179
32,645,463
1,245,788
1,371,444
1,580,512
1,753,803
1,753,8031,580,5121,371,4441,245,78832,645,46333,049,17932,281,55815,774,87815,117,61214,416,36714,233,23613,762,05910,319,27710,788,14012,171,07214,396,76711,017,5101,919,1712,125,7582,117,6567,584,0757,032,2817,378,1037,333,4782,684,5132,195,9422,443,0383,749,6352,405,039
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
7,150,898
7,236,290
7,347,019
5,710,663
4,909,486
4,577,307
5,784,629
6,924,131
4,452,420
4,702,145
4,791,943
4,745,916
4,306,956
6,528,479
6,831,870
6,294,947
8,102,292
12,925,019
13,009,463
1,544,138
1,544,13813,009,46312,925,0198,102,2926,294,9476,831,8706,528,4794,306,9564,745,9164,791,9434,702,1454,452,4206,924,1315,784,6294,577,3074,909,4865,710,6637,347,0197,236,2907,150,898000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
198,500
182,190
154,346
126,501
98,620
509,737
497,599
441,504
374,182
341,276
261,542
181,068
166,743
298,945
340,327
274,351
169,263
199,177
283,086
238,126
238,126283,086199,177169,263274,351340,327298,945166,743181,068261,542341,276374,182441,504497,599509,73798,620126,501154,346182,190198,500000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000
> Total Stockholder Equity
320,100,826
322,018,581
322,879,946
323,052,800
322,826,230
323,466,151
324,301,103
324,320,368
324,335,049
323,572,219
327,234,910
326,549,504
345,489,453
343,725,889
343,963,029
344,293,855
347,476,093
341,179,333
341,932,710
342,606,241
345,909,591
342,062,504
441,037,822
444,276,376
445,567,209
427,147,056
415,367,050
419,746,472
382,753,680
382,753,680419,746,472415,367,050427,147,056445,567,209444,276,376441,037,822342,062,504345,909,591342,606,241341,932,710341,179,333347,476,093344,293,855343,963,029343,725,889345,489,453326,549,504327,234,910323,572,219324,335,049324,320,368324,301,103323,466,151322,826,230323,052,800322,879,946322,018,581320,100,826
   Retained Earnings 
392,471,888
393,402,749
393,711,589
394,150,116
393,890,783
395,475,741
396,223,681
396,112,396
396,955,003
392,899,035
396,335,213
396,008,444
402,367,641
401,769,475
401,797,030
402,444,231
404,579,631
398,125,446
398,823,072
399,574,810
402,810,463
402,190,716
502,095,641
505,379,119
506,894,168
492,733,913
491,519,278
496,000,813
459,164,063
459,164,063496,000,813491,519,278492,733,913506,894,168505,379,119502,095,641402,190,716402,810,463399,574,810398,823,072398,125,446404,579,631402,444,231401,797,030401,769,475402,367,641396,008,444396,335,213392,899,035396,955,003396,112,396396,223,681395,475,741393,890,783394,150,116393,711,589393,402,749392,471,888
   Accumulated Other Comprehensive Income 00000000000000000000000000000
   Capital Surplus 00000000000000000000000000000
   Treasury Stock00000000000000000000000000000



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue78,053,232
Cost of Revenue-41,966,787
Gross Profit36,086,44536,086,445
 
Operating Income (+$)
Gross Profit36,086,445
Operating Expense-103,299,797
Operating Income-25,246,565-67,213,353
 
Operating Expense (+$)
Research Development588,083
Selling General Administrative22,780,735
Selling And Marketing Expenses-
Operating Expense103,299,79723,368,818
 
Net Interest Income (+$)
Interest Income8,454,962
Interest Expense-23,874
Other Finance Cost-1
Net Interest Income8,431,087
 
Pretax Income (+$)
Operating Income-25,246,565
Net Interest Income8,431,087
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-21,344,936-25,246,565
EBIT - interestExpense = -23,874
-20,940,893
-20,917,019
Interest Expense23,874
Earnings Before Interest and Taxes (EBIT)--21,321,062
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-21,344,936
Tax Provision--404,043
Net Income From Continuing Ops-20,940,893-20,940,893
Net Income-20,940,893
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--8,431,087
 

Technical Analysis of Ilsung Pharm
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Ilsung Pharm. The general trend of Ilsung Pharm is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Ilsung Pharm's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Ilsung Pharm.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 20,500 < 24,500 < 24,600.

The bearish price targets are: 18,980 > 18,710 > 18,070.

Tweet this
Ilsung Pharm Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Ilsung Pharm. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Ilsung Pharm Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Ilsung Pharm. The current macd is -740.32027736.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Ilsung Pharm price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Ilsung Pharm. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Ilsung Pharm price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Ilsung Pharm Daily Moving Average Convergence/Divergence (MACD) ChartIlsung Pharm Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Ilsung Pharm. The current adx is 23.09.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Ilsung Pharm shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Ilsung Pharm Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Ilsung Pharm. The current sar is 18,342.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Ilsung Pharm Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Ilsung Pharm. The current rsi is 38.15. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Ilsung Pharm Daily Relative Strength Index (RSI) ChartIlsung Pharm Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Ilsung Pharm. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Ilsung Pharm price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Ilsung Pharm Daily Stochastic Oscillator ChartIlsung Pharm Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Ilsung Pharm. The current cci is -51.51989886.

Ilsung Pharm Daily Commodity Channel Index (CCI) ChartIlsung Pharm Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Ilsung Pharm. The current cmo is -18.42181385.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Ilsung Pharm Daily Chande Momentum Oscillator (CMO) ChartIlsung Pharm Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Ilsung Pharm. The current willr is -52.72108844.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Ilsung Pharm is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Ilsung Pharm Daily Williams %R ChartIlsung Pharm Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Ilsung Pharm.

Ilsung Pharm Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Ilsung Pharm. The current atr is 670.17.

Ilsung Pharm Daily Average True Range (ATR) ChartIlsung Pharm Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Ilsung Pharm. The current obv is 2,635,257.

Ilsung Pharm Daily On-Balance Volume (OBV) ChartIlsung Pharm Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Ilsung Pharm. The current mfi is 21.90.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Ilsung Pharm Daily Money Flow Index (MFI) ChartIlsung Pharm Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Ilsung Pharm.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-20MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-31WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-13MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-15MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-24MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Ilsung Pharm Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Ilsung Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.152
Ma 20Greater thanMa 5020,371.000
Ma 50Greater thanMa 10021,850.400
Ma 100Greater thanMa 20022,388.700
OpenGreater thanClose20,000.000
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Ilsung Pharm with someone you think should read this too:
  • Are you bullish or bearish on Ilsung Pharm? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Ilsung Pharm? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Ilsung Pharm

I send you an email if I find something interesting about Ilsung Pharm.


Comments

How you think about this?

Leave a comment

Stay informed about Ilsung Pharm.

Receive notifications about Ilsung Pharm in your mailbox!